Material
H
IV type 1 (HIV-1) infection is characterized by viremia, progressive depletion of CD4 T lymphocytes, and the development of AIDS. Although the CD4 T cell count provides an indication of the intactness of the CD4 T cell compartment and its ability to prevent opportunistic infections, the peripheral blood viral load provides an indication of how rapidly the CD4 T cell compartment will be depleted as a result of pathological processes driven by viral replication (1) . The profound contribution of highly active antiretroviral therapy is to interrupt HIV replication with a resultant decrease in viral load and an increase in CD4 T cell count and function (2) . Therefore, the viral load assay is one of the most sensitive and reliable parameters to assess highly active antiretroviral therapy effectiveness, despite the fact that use of immunological criteria is suggested for making treatment decisions about changing from a first-to a second-line regimen under the current World Health Organization HIV-1 treatment guidelines in resource-limited settings (3) (4) (5) . Similarly, failure of intermittent antiretroviral therapy is marked by a strong viral rebound followed by more severe and longer depletion of CD4 T cells and disease progression (6, 7) . Notably, viral replication substantially contributes to the viral load in an infected individual, and thus plays a critical role in HIV-1/AIDS pathogenesis.
HIV-1 largely infects and replicates in activated human CD4 T cells. In particular, HIV-1 shows a preferential replication in Th2 and Th0 subsets of activated effector T cells without clearly defined reasons. Early studies found that HIV-1 infection might induce a shift in the relative proportion of different CD4 Th cell subsets, and the virus preferentially replicated in CD4 T cells that produced Th2-type cytokines (8, 9) . This preferential replication phenomenon by HIV-1 was later confirmed in several studies by using primary HIV-1 isolates capable of binding either the CCR5 or the CXCR4 chemokine receptors required as coreceptors for viral entry into CD4 T cells (10) (11) (12) (13) (14) . However, these studies were conducted in vitro using conditionally polarized Th0, Th1, and Th2 clones derived from HIV-1 patients or healthy donors, and thus not necessarily reflecting infection of CD4 T cell subsets in vivo. Therefore, analysis of HIV-1 expression levels ex vivo in different CD4 T cell populations from infected individuals will be much more relevant to understanding HIV-1/AIDS progression (15) .
Because of the significance of viral replication in HIV-1/AIDS pathogenesis, it is important to understand the mechanism un-derlying HIV-1 preferential replication in Th2 and/or Th0 effector CD4 T cells. Initially, one of the possible explanations put forward was related to a difference on T cell subsets in expression of chemokine receptors required for HIV-1 infection. Namely, Th1 cells express more CCR5 (16) and consequently are more easily infected by R5-tropic HIV-1; conversely, Th2 cells express a high density of CXCR4 (17) and are more susceptible to X4-tropic HIV-1 infection. However, over the time course of infection, R5 viral replication surprisingly increased in Th2 cells and drastically decreased in Th1 cells. By comparison, X4 viruses consistently maintained a high level of replication in Th2 cells and a low level in Th1 cells (10, 11) . In addition, a proposed blockade of CCR5 by associative ligands, such as RANTES, MIP-1a, and MIP-1b, does not provide a satisfactory explanation because they seem to be generated and secreted constitutively, and a variety of chemokines might play different roles during HIV-1 replication (10, 18, 19) . Thus, differential chemokine receptor expression does not appear to explain increased HIV-1 expression in IL-4-producing CD4 T cells.
An alternative hypothesis is that HIV-1 gene transcription influences differential viral replication in host CD4 T cell subsets (20) . Along this line, in this study, we investigate whether a Th2-specific transcriptional mechanism affects HIV-1 replication. Specifically, we focus on a Th2-restricted factor, c-maf, exploring a potential mechanism that augments HIV-1 gene expression in IL-4-producing CD4 T cells. The proto-oncogene, c-maf, is the cellular counterpart of oncogenic v-maf (21) . The c-maf protein belongs to a large family of basic region leucine zipper domain transcription factors and exerts its transcriptional role through binding to a Maf recognition element (MARE) (22) . c-maf is expressed in Th2 but not Th1 clones, and plays a critical and selective role in transcriptional activation of IL-4 (in conjunction with NFAT), IL-10, and IL-21 cytokine gene transcription (23) (24) (25) (26) . NFAT transcription factors, especially NFAT2, are also involved in the positive regulation of IL-4 gene expression (27) . Moreover, NFAT2 is capable of inducing a highly permissive state for HIV-1 replication in primary CD4 T cells (28) . NFAT proteins, as well as their relatively homologous Rel family members, NF-kB RelA (p65) and p50, have been clearly shown to directly bind to and augment transcription of the HIV-1 long terminal repeat (LTR) via the dual proximal NF-kB/NFAT binding sites (28, 29) . Moreover, they have even been reported to be essential for enhancing HIV-1 transcription (30) (31) (32) and likely play a role in governing latency maintenance (33) . In this article, we show the transcription factor, c-maf, contributes to increased HIV-1 transcription in IL-4-producing CD4 T cells via binding to the LTR in cooperation with NFAT2 and NF-kB p65 specifically. Our studies provide new insight into the preferential replication of HIV-1 in IL-4-producing CD4 T cells and further suggest means to disrupt this increased HIV-1 expression or, alternatively, augment transcription of latently infected cells.
Materials and Methods

Plasmids and reagents
The original expression vectors for c-maf from Dr. Xiaojing Ma (34) and for NFAT2 (29) have been described. Luciferase reporter plasmids pLTR-Luc and pIL-4-Luc were previously described (35) . The pLTR-GFP, pIFN-g-GFP, and pIL-4-GFP constructs were generated by subcloning the 39 HIV-1 LTR segment (598 bp), human IFN-g (hIFN-g) promoter segment (646 bp), and human IL-4 (hIL-4) promoter segment (805 bp), respectively, into pEGFP-N1 to substitute the CMV promoter (Clontech). Similarly, the pcmaf-GFP plasmid was generated with the minimum c-maf-binding promoter, in which two tandem MARE consensus sequences (59-TGCTGACTCAGCA-39) were inserted just upstream of the minimal c-maf-binding fragment (position 2206 to +30) of the hIL-10 promoter (34). rIL-2 was supplied by the National Institutes of Health AIDS Research and Reference Reagent Program (Germantown, MD). rIL-4 was obtained from R&D Systems. Fluorescenceconjugated anti-IL-4, anti-IFN-g, anti-CXCR4, and anti-CCR5 Abs were purchased from BD Bioscience, as was 7-amino-actinomycin D. Fluorescenceconjugated anti-HIV-1 core Ag (p24) Ab was purchased from Beckman Coulter.
Cell isolation and expansion of IL-4-producing CD4 T cells
Institutional Review Board approval for protection of human subjects was obtained from the University of Pennsylvania and the University of Alabama at Birmingham. Primary human peripheral blood CD4 T cells from healthy donors were isolated by negative selection using a proprietary Ab mix (StemCell Technologies) as described previously (36) . The primary T cells were activated with PHA (200 ng/ml) for 3 d in the presence of IL-4 (10 ng/ml) and irradiated (3000 rad) syngeneic PBMCs to polarize IL-4-producing CD4 T cells (37) . The activated cells were cultured for another 8-12 d in the presence of rIL-2 (30 IU/ml) and rIL-4 (10 ng/ml) with fresh culture media replacement every 2-3 d.
Transient transfection and reporter gene assays
Freshly isolated human CD4 T cells were transiently transfected with expression vector(s), alone or in combination with GFP or luciferase reporter plasmids, using Human T cell Nucleofector kits (Lonza), as described elsewhere (38) . In primary infection experiments, the transfected cells were activated with PHA (1.5 mg/ml) and rIL-2 (20 U/ml) for 3 d followed by HIV-1 infection. In c-maf knockdown experiments, the polarized CD4 T cells were transiently transfected with a small interfering RNA (siRNA) expression vector or its control as previously detailed (39) . The cells were then cultured in the presence of rIL-2 (30 U/ml) before analysis. All GFP reporter expression was detected by flow cytometry.
Electricity mobility shift assay and in vitro footprinting
Nuclear extracts were prepared from polarized human CD4 T cells. Oligonucleotide probes were labeled with g-[ (Table I) . Electricity mobility shift assay was performed as previously described (36) . Baculovirusgenerated recombinant mafK and NFAT2 were prepared and studied for binding to the proximal HIV-1 LTR by in vitro footprinting as previously described (29) .
Chromatin immunoprecipitation and real-time PCR
Cytokine polarized human CD4 T cells were specifically infected with the HIV-1 NL4-3-GFP strain, which was kindly provided by Dr. David N. Levy (New York University). Before the chromatin immunoprecipitation (ChIP) assay, HIV-1-infected cells (GFP + ) were live sorted by flow cytometry after activation with PMA and ionomycin for 3 h. The ChIP assay was performed on the sorted GFP + cells according to the product guidelines (Upstate Biotechnology). Purified DNA precipitated by anti-NFAT1, -NFAT2, -NF-kB p65, -NF-kB p50, -c-maf, -Oct1 Abs, or IgG (Santa Cruz Biotechnologies) was subjected to real-time PCR. The amplicon was designed to overlap with the dual NF-kB/NFAT sites and the nearby upstream MARE site within the proximal HIV-1 LTR (Table I ). The reaction was performed with the TaqMan Universal PCR Master Mix (Applied Biosystems). Fold transcription factor binding relative to negative control Ab precipitation was calculated by the formula, fold binding = 2 (ΔCt) , where DCt is calculated as cycle threshold (Ct) of Ab control minus Ct of the transcription factor Ab of interest.
HIV-1 infection and p24/gag detection
The HIV-1 virus strains, NL4-3, 89.6, Bal-1, were supplied by the Center for AIDS Research of the University of Pennsylvania. The NA420/BB3 HIV-1 strain was kindly provided by Dr. Phillip Smith (University of Alabama at Birmingham, Birmingham, AL). The activated (or polarized) CD4 T cells were infected with viral stock (p24, 50-100 ng/10 6 cells) in the presence of DEAE-Dextran (4 mg/ml) for 2 h or overnight at 37˚C. The cells were then cultured in the presence of rIL-2 for an additional 3-5 d before analysis. Intracellular p24/gag staining and analysis was performed as previously described (40) .
Intracellular cytokine analysis and cell proliferation assays
Cytokine-polarized CD4 T cells were HIV-1 (or mock) infected and then stimulated with PMA (25 ng/ml) and ionomycin (1.5 mM) for 4-6 h at 37˚C in the presence of brefeldin A (10 mg/ml) followed by intracellular staining according to the manufacturer's suggestions (BD Pharmingen). For proliferation assays during HIV-1 infection, cytokine-polarized cells were first labeled by using CFSE before viral infection. Two days later, the CFSElabeled, HIV-1-infected cells were stimulated with anti-CD3 (5 mg/ml) and anti-CD28 (5 mg/ml) Abs in the presence of irradiated syngeneic PBMCs for another 3 d before analyzing intracellular cytokine production, CFSE dilution, and HIV-1 p24 expression. Flow cytometry data were collected using a BD Calibur or LSRII flow cytometer, and analyzed using FlowJo software (Tree Star).
Isolation of IL-4 + cells and detection of HIV-1 mRNA from HIV-1-infected individuals
Sixty milliliters of peripheral blood was collected from HIV-1-infected individuals with high viral titers (viral loads were between 65,000 and 950,000 copies/ml; CD4 counts ranged between 127 and 350/ml). CD4 + cells were then purified by negative selection using a proprietary Ab mix as previously described (35), followed by stimulation of PMA plus ionomycin overnight to allow for IL-4 expression. IL-4 + and IL-4 2 cells were then separated by using IL-4 cell enrichment and detection kits (Miltenyi Biotech) according to the product guidelines. RNA was isolated from each population of cells and converted to cDNA with SuperScript III (Invitrogen) reverse transcriptase. Two rounds of PCR amplification were carried out to determine the HIV-1 mRNA abundance as described previously (41) . In brief, the first round of PCR was performed on a conventional PCR machine with the setting as follows: 94˚C for 3 min, followed by 21 cycles of 94˚C for 30 s, 55˚C for 30 s, and 72˚C for 1 min. These products were subsequently used as templates for the second, seminested, real-time PCR, performed on the iQ5 multicolor real-time detection machine (Bio-Rad). The TaqMan detection chemistry was used, and real-time PCR settings were as follows: 50˚C for 2 min, then 95˚C for 10 min, followed by 45 cycles of 95˚C for 15 s and 60˚C for 1 min. Real-time RT-PCR analyses were also performed for 18S RNA, IL-4, and c-maf mRNA levels. Primers and probes used for detection are listed in Table I . Differences in message levels between IL-4 + and IL-4 2 cells in individual patients were calculated using the Wilcoxon matched paired test (GraphPad Prism 5), and statistical significance was set at p , 0.05.
Results
HIV-1 preferentially replicates in IL-4-producing CD4 T cells
The majority of previous studies examining HIV-1 infectivity and replication were carried out using in vitro separately derived Th1 and Th2 cell lines from HIV-1-infected individuals, healthy donors, or umbilical cord blood samples. HIV-1 infection and replication efficiency was then compared by monitoring p24/gag levels in culture supernatants (8, 9) . There are, however, major shortcomings of these types of studies: 1) the infection conditions differed for the different environments used to support the Th1 and Th2 cell lines, and 2) assaying the p24 level in the bulk culture supernatant does not provide data at an individual cell level within a bulk population.
To study the fidelity of HIV-1 preferential replication in Th2 cells and to overcome the two aforementioned problems, we generated in vitro, using a combination of IL-2 and IL-4, an admixture of To further exclude the potential influences of viral tropisms on viral replication described elsewhere (42) , an X4-tropic strain, NL4-3, a R5-tropic strain, Bal-1, and a X4R5 dual tropic strain, 89.6, were compared for their abilities to infect an admixture of polarized Th0, Th1, and Th2 CD4 T cells. To our surprise, IL-4-producing cells consistently and preferentially support HIV-1 viral expression irrespective of the viral tropism (Fig. 1B) . Furthermore, this preference is consistent using different initial stimuli (anti-CD3 plus anti-CD28 mAb versus PHA) to polarize the host cells (Fig. 1C) . As a complementary alternative approach, we also show that surface CXCR4 expression is similar between IFN-g + and IL-4 + CD4 T cells, whereas CCR5 expression is higher on IFN-g + cells after T cell activation (Supplemental Fig. 2A ). Nevertheless, both X4-and R5-tropic HIV-1 strains are expressed at similar levels in CXCR4 + and CCR5 + CD4 T cells (Supplemental Fig. 2B ) despite increased expression in IL-4 + relative to IFN-g + CD4 T cells (Supplemental Fig. 2C ). Thus, differences in chemokine receptor expression or in HIV-1 viral tropism do not explain increased HIV-1 expression in IL-4 + CD4 T cells. To exclude the possibility that high-level expression of HIV-1 in IL-4-producing T cells is a result of a relative rapid growth during HIV-1 infection, we labeled cytokine-polarized CD4 T cells by using CFSE to allow for tracking of cell proliferation during HIV-1 infection. As shown in increase in HIV-1 mRNA between IL-4-producing versus nonproducing cells) for the group as a whole ( Fig. 2A) . As predicted, based on the importance of c-maf for IL-4 expression (24), c-maf mRNA levels were detected to any significant level only in the IL-4 + cells (Fig. 2B) . Likewise, IL-4 mRNA was essentially limited to IL-4-producing cells (Fig. 2C) . Thus, HIV-1 mRNA levels are ∼10-fold higher, on average, in c-maf-expressing, IL-4-producing CD4 T cells from peripheral blood of HIV-1-infected individuals. Because the cells were sorted based on IL-4 expression, the relative levels of IL-4 and associated c-maf are markedly higher in the IL-4 + cells compared with the IL-4 2 cells (e.g., 2 10-40 ) as expected. However, because the difference in HIV-1 was expected to be only near 2-fold (based on the in vitro data, Fig. 1 (Fig. 4A) . We next explored the ability of c-maf to bind the HIV-1 LTR.
c-maf belongs to a large family of maf proteins, all of which share a very homologous DNA-binding domain (44) . To facilitate preparation of recombinant protein, we tested the ability of mafK, a small maf family member with a virtually identical DNA binding domain to c-maf, to bind to the proximal HIV-1 LTR by in vitro footprinting. mafK clearly protected DNA residues from DNase I digestion (i.e., bound the LTR in vitro) corresponding to the predicted MARE (Fig. 4B) . Moreover, rNFAT2 in conjunction with mafK extended the protected residues through the NF-kB/NFAT region (Fig. 4B) . Interestingly, even though there are 10 residues between the predicted MARE and the NF-kB/NFAT region, the site protected by mafK is adjacent to the NFAT2 binding site. This suggests that the two factors may interact and potentially cooperate when binding to the proximal HIV-1 LTR.
The ability of NFAT and NF-kB proteins present in polarized human CD4 T cells to bind in conjunction with c-maf on the proximal HIV-1 LTR was then explored. Prior work, including our own, has shown that rNF-kB family members, p65 and p50, and NFAT family members, NFAT1 and NFAT2, are all capable of binding to the HIV-1 LTR NF-kB/NFAT sites in vitro (29, 31) . In the present studies, the LTR NF-kB/NFAT dual-site probe (primers and probes used for detection are listed in Table I ) was incubated with activated IL-4 polarized CD4 T cell nuclear extracts in the presence of specific anti-transcription factor Abs during the gel shift assays. Interestingly, NF-kB p65 is preferentially present in the shifted complexes relative to NF-kB p50, and NFAT2 preferentially binds the LTR over NFAT1 (Fig. 4C) . This preferential binding of NF-kB p65 and NFAT2 is unique to the HIV-1 LTR and not a function of the particular supershifting Abs, as NFkB p50, NF-kB p65, NFAT1, and NFAT2 contained in the identical nuclear extracts were all relatively equally supershifted by the same Abs when tested for binding to NF-kB and NFAT sites derived from the Igk and IL-2 promoters, respectively (Fig. 4C) . Thus, the preferential binding of NF-kB p65 and NFAT2 to the HIV-1 LTR may reflect subtle differences in the HIV-1 LTR DNA binding or flanking sequences, and/or cooperative protein-protein interactions that can only be detected in physiologically relevant CD4 T cell nuclear extracts.
Binding of c-maf to the HIV-1 LTR in vitro was also explored by gel shift assay. A gel retarded band, from nuclear extracts from IL-4-primed CD4 T cells, migrated identically comparing a consensus MARE probe and a probe containing the putative HIV-1 LTR MARE (Supplemental Fig. 3 ). These bands were both fully competed with excess unlabeled self-probe, and they were both partially diminished in intensity (decreased by 48% for the consensus MARE probe, and decreased by 40% for the HIV-1 MARE probe, by densitometry) using a blocking anti-c-maf Ab (Supplemental Fig.  3 ). This suggests that c-maf present in IL-4-primed CD4 T cell nuclear extracts is capable of binding the HIV-LTR MARE in vitro just upstream of the dual NF-kB/NFAT sites.
To confirm the binding of c-maf and the individual NF-kB and NFAT family members to the HIV-1 LTR in vivo, we infected IL-4-primed human CD4 T cells with the NL4.3-GFP strain (45) . ChIP assays were then performed using the purified GFP + (infected) cells with anti-c-maf, -NF-kB, and -NFAT Abs, and immunoprecipitated DNA was quantified by real-time PCR. We previously demonstrated that octamer transcription factors do not bind the HIV-1 LTR in vitro (36) , so anti-Oct1 was chosen as a negative transcription factor Ab control, in addition to the isotype control Ab. As shown in Fig. 4D , the fold binding to the HIV-1 LTR for each transcription factor was calculated according to the respective Ct value of the specific transcription factor Ab relative to the IgG control Ab. Similar to in vitro binding results (Fig. 4B, 4C , Supplemental Fig. 3) , there was clear evidence for binding to the HIV-1 LTR in vivo for c-maf, NF-kB p65, and NFAT2, but not for Oct1, NF-kB p50, and NFAT1 (Fig. 4D) . Not only did this imply a role for c-maf in HIV-1 regulation, but it confirmed the preferential binding of unique NF-kB (p65 over p50) and NFAT (NFAT2 over NFAT1) transcription factor family members to the HIV-1 LTR.
c-maf cooperates with NFAT2 and NF-kB p65 to augment HIV-1 LTR transcription
The functional significance of c-maf alone, c-maf plus NFAT2, or cmaf plus NF-kB p65 to HIV-1 expression was next explored. First, primary human CD4 T cells were transiently transfected with an HIV-1 LTR-driven GFP reporter plasmid and cotransfected with cmaf, NFAT2, NF-kB p65, c-maf plus NFAT2, or c-maf plus NFkB p65 expression vectors. It is evident that c-maf alone increases HIV-1 LTR activity (mean fluorescence intensity [MFI]: 127 to 399) without increasing cell survival (,10% difference in cell number after transfection). The increased HIV-1 LTR transcriptional activity is further and significantly enhanced when coexpressing NFAT2 (MFI: 438) or NF-kB p65 (MFI: 776) (Fig. 5A, top panel) , suggesting a cooperative interaction between c-maf and NFAT2 and NF-kB p65.
Was this cooperative transcriptional activation by these factors relatively unique to the HIV-1 LTR? This possibility was explored by comparing hIL-4 promoter-, hIFN-g promoter-, and HIV-1 LTR-driven GFP reporter gene activity in primary human CD4 T cells. As expected, c-maf notably increases HIV-1 LTR and hIL-4 promoter (MFI: 35.9-123) transcriptional activity, but only modestly augments hIFN-g promoter activity (MFI: 62-133). Increased HIV-1 LTR and IL-4 promoter transcription can be augmented in the presence of either NFAT2 or NF-kB p65 (Fig.  5A, top and middle panels) . The activity of each promoter was calculated [%(+) cells 3 MFI] and averaged from five independent experiments and is shown in Fig. 5B . NF-kB p65, but not NFAT2, increased individual promoter transcription. However, both significantly cooperate with c-maf to increase LTR and IL-4, but not IFN-g promoter transcription. These results demonstrate that c-maf in cooperation with NFAT2 or NF-kB p65 notably augments HIV-1 LTR and hIL-4 promoter, but not hIFN-g promoter, transcription.
Inhibiting c-maf expression dramatically decreases HIV-1 LTR activity
The role of endogenous c-maf during HIV-1 transcription was tested by introduction of c-maf-specific siRNA into IL-4 polarized CD4 T cells using our own published protocol (39). We first determined the efficiency and specificity of c-maf-specific siRNA designed by ourselves by verifying decreased expression of endogenous c-maf in IL-4 polarized CD4 T cells at both the mRNA and protein levels, and a decreased activity of a c-maf-responsive reporter plasmid, when transfecting c-maf siRNA into those cells (Supplemental Fig. 4A-C, respectively) . Therefore, the c-mafspecific siRNA can be used to assess the role of endogenous c-maf during HIV-1 infection.
To first test HIV-1 LTR transcriptional activity, we cotransfected IL-4-producing CD4 T cells with an HIV-1 LTR-GFP reporter plasmid plus the c-maf-specific siRNA expression vector or scrambled control. Compared with control siRNA, HIV-1 transcriptional activity is notably diminished in the presence of c-maf siRNA. Moreover, increasing doses of the c-maf-specific siRNA demonstrate dose-dependent inhibition of HIV-1 transcription (Fig. 6A) . Similarly, c-maf-specific siRNA inhibits hIL-4 promoter-but not hIFN-g promoter-driven transcription in IL-4-producing CD4 T cells (Fig. 6B, left panel) . When visualized as percentage inhibition of transcription averaged over several experiments, it is clear that c-maf-specific siRNA inhibits both HIV-1 LTR-and hIL-4 promoter-driven transcription, but not transcription of the hIFN-g promoter (Fig. 6B, right panel) . Thus, the c-maf-specific siRNA is specific to its target genes, and the results with its use suggest that endogenous c-maf present in IL-4-producing CD4 T cells is not only important for optimal IL-4 gene transcription but for that of HIV-1 transcription as well. (Fig. 7A ). Using another model system, we transfected HEK-293T cells with increasing amounts of a c-maf expression plasmid followed by infection with HIV-1 NLENG-vsvg-GFP. In comparison with the control vector, c-maf was capable of increasing HIV-1 expression in a dose-dependent manner (Fig. 7B) . Thus, enhanced c-maf expression led to increased HIV-1 expression in two different cell lines. Because c-maf is known to cooperate with NFAT in driving IL-4 transcription (46), we explored the ability of c-maf to cooperate with NFAT2 in driving HIV-1 expression. HEK-293T cells were transfected with c-maf alone, NFAT2 alone, or cotransfected with c-maf and NFAT2 expression vectors. Although NFAT2 did not increase HIV-1 expression alone, NFAT2 clearly augments c-mafenhanced HIV-1 expression, particularly at day 2 postinfection (Fig. 7C) . Most importantly, we wished to confirm this effect in primary human CD4 T cells. CD4 T cells were first transfected with control, c-maf, NFAT2, or NF-kB p65 expression vectors before HIV-1 NL4-3 infection. HIV-1 expression was analyzed at 3-5 d postinfection. Although none of the transcription factors in isolation dramatically augments HIV-1 expression in primary CD4 T cells (Fig. 7D, top row) , when all three expression vectors (c-maf, NFAT2, and NF-kB p65) were cotransfected, the combined overexpression of these three factors notably augments HIV-1 viral expression (Fig. 7D, bottom row) . Thus, there does appear to be a cooperative/synergistic effect of c-maf, NFAT2, and NF-kB p65 on increasing HIV-1 expression in primary human CD4 T cells.
Discussion
In exploring a previously noted shift from a Th1 to Th2/Th0 phenotype occurring during HIV-1 infection and progression to AIDS, investigators found a bias of HIV-1 replication in different CD4 T cell subsets or clones (8, 9) . Focusing on HIV-1 infection and expression in individual cells from a bulk culture, we confirm that HIV-1 preferentially replicates in either Th2 or Th0, namely, IL-4-producing, cells. Attempting to explain this phenomenon, others have previously reported that cloned Th1 cells are more susceptible to HIV-1-induced apoptosis (47) . However, using cytokine primed bulk CD4 T cells, we demonstrate that preferential HIV-1 expression is not secondary to a rapid growth of IL-4-producing cells (Fig. 1D) , nor is it related to an increased rate of HIV-1-triggered apoptosis of non-IL-4-producing cells (Supplemental Fig. 1 ). Moreover, we show that increased HIV-1 expression in IL-4 + cells is independent of viral tropism (Fig. 1B ) and the level of chemokine receptor expression (Supplemental Fig. 2) . These results are consistent with the majority of previous reports (10) (11) (12) (13) (14) 18) , but differ from others where the HIV-1 R5 strain alone or both R5 and X4 strains were found to replicate (equally) in Th1 and Th2 cells (48) (49) (50) . Although our in vitro infection is not identical to the infection occurring in vivo, by using primary human CD4 T cells in bulk culture, it more closely resembles the natural infection process than cell lines or clones. Therefore, we believe our results are pathophysiologically relevant.
The findings of high levels of the ex vivo HIV-1 mRNA in IL-4-producing CD4 T cells from infected individuals, and increased HIV-1 LTR activity in IL-4-polarized human CD4 T cells in vitro, stimulated exploration of whether an IL-4-restricted transcriptional mechanism was involved in optimal HIV-1 gene expression. Accordingly, we identified a functional binding site for the Th2-restricted transcription factor, c-maf, in the proximal region of the HIV-1 LTR adjacent to the dual NF-kB/NFAT sites. In addition, NF-kB factors, p65 over p50, and NFAT factors, NFAT2 over NFAT1, were shown to preferentially bind to the LTR dual NFkB/NFAT sites. It has been reported that both p65 and NFAT2 are increased in hIL-4 expression (51, 52). In this regard, a synergistic effect between c-maf and NFAT2, or between c-maf and p65, specifically increased HIV-1 LTR and hIL-4 promoter, but not hIFN-g promoter, transcriptional activity. Taken together, c-maf contributes to increased HIV-1 transcription in IL-4-producing T cells via binding to the proximal LTR in cooperation with specific NFAT (NFAT2) and NF-kB (p65) family members.
Based on our findings, as well as a recent report describing a physical interaction specifically between NFAT2 and NF-kB p65, which synergistically promotes cardiac hypertrophy and ventricular remodeling (53), we postulate that a similar cooperative interaction among c-maf, NFAT2, and NF-kB p65 contributes to increased HIV-1 transcription in IL-4 + CD4 T cells. Moreover, this synergism is likely an important mechanism contributing to the frequently observed preferential replication of HIV-1 in IL-4-producing CD4 T cells. Nevertheless, HIV-1 may lower c-maf expression, as recently suggested by Ahmad and colleagues (54) , thus placing more importance on a cooperative interaction of transcription factors needed to promote HIV-1 transcription.
HIV-1 gene transcription and expression regulate viral replication, and consequently influence AIDS progression. Along these lines, it has been reported that HIV-1 LTR transcriptional activity is increased 3-and 10-fold in neonatal cord blood T lymphocytes and macrophages, respectively, in comparison with adult blood cells (55) . The authors (55) conclude that it is increased viral gene expression derived from enhanced LTR transcription, rather than differences in cell proliferative capacities, cells surface receptor expression, viral RNA genome reverse transcriptional activity, or translocation of the preintegration complex into the nucleus, that directly results in a higher level of viremia and faster disease progression in neonates than in adults. They further identify a complex transcriptional mechanism regulating control of HIV-1 gene transcription and expression in neonatal mononuclear cells (20) . In this study, we find an 8.6-fold higher HIV-1 LTR transcriptional activity and almost 2-fold higher HIV-1 p24 expression in IL-4-producing CD4 T cells compared with non-IL-4-producing T cells. Therefore, one may postulate that viral production in Th2 and Th0 cells substantially contributes to viral load and viremia during HIV-1 infection and AIDS progression. Over a decade or more of infection, even 2-fold differences in viral production will cause substantial differences in total viral burden. Considering the hypothesis that a Th1 to Th2 (or Th0) shift occurs under certain circumstances during HIV-1 infection (8, 9, 56) , it seems reasonable that relatively high levels of IL-4 will help maintain the stability of the Th2 compartment and concomitantly inhibit the generation of the Th1 compartment. This scenario predicts facilitation of HIV-1 proliferation via the virus taking advantage of Th2 cell-specific transcriptional machinery to optimize its replication whereas avoiding Th1-mediated antiviral immune responses. Moreover, individuals who resist HIV-1 infection by secreting an IL-4 variant with a deletion of exon 2, a natural antagonist of IL-4, further support pivotal roles of IL-4 and Th2 cells during HIV-1 infection (57, 58) . Taking together these previous reports and this study, we propose that the preferential support of HIV-1 replication by IL-4-producing T cells, along with the relative cell stability in the presence of IL-4, are critical pathophysiologic consequences of HIV-1 infection and AIDS progression. Our findings are of significant importance in helping to increase our current understanding of HIV-1 biology and AIDS pathogenesis.
